MedDay’s MD1003, a Biotin Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials  

The biotechnology company MedDay, recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its drug product MD1003 in patients with multiple sclerosis (MS).

Specifically, the trials included people with “not active” progressive MS and those with either relapsing or progressive MS and visual loss, respectively. Data presented at the recent American Academy of Neurology 2016 Annual Meeting in Vancouver, Canada, demonstrated better efficacy in reversing disease progression than a drug has previously achieved in not-active progressive MS.

Learn more about MD1003 here: http://bit.ly/1Uh0j6M

Read full article here: http://bit.ly/1qTwPQK